Jakob Dupont, MD: Epstein-Barr Virus Targeted Agent ATA188 in Progressive MS

Jakob Dupont, MD: Phase 1 Data on Cell Therapy for Progressive MSПодробнее

Anti-EBV trial shows promise in Progressive MSПодробнее

ATA188: an allogeneic EBV-specific T cell therapy for progressive MSПодробнее

Characterization of ATA188: an off-the-shelf therapy for MSПодробнее

Advances in cell-based therapies for MSПодробнее

AM2020-Willmer-ID27Подробнее

BEHIND-MS: Exploring the Link Between Epstein-Barr Virus and Multiple SclerosisПодробнее

ATA188 in EBV+ progressive multiple sclerosisПодробнее

ATA 188 for Multiple Sclerosis (anti-EBV neurogenic t-cell therapy from Atara Biotherapeutics)Подробнее

New research shows link between Epstein-Barr virus and multiple sclerosisПодробнее

Episode 229: Evidence Shows MS Is Triggered by the Epstein-Barr Virus with Dr. Kassandra MungerПодробнее

Ask an MS Expert: The Role of Epstein-Barr Virus in MSПодробнее

MS Minute #5 - Progressive MS & Viruses as MS TriggersПодробнее

Epstein–Barr VirusПодробнее

Epstein-Barr virus as a predominant trigger of multiple sclerosisПодробнее

Causes of MS - MS in a minuteПодробнее

ATA3219, ATA3271 & ATA188: T-Cell immunotherapy products in developmentПодробнее

Neurology News Network: week of October 16Подробнее